Within a year after the discovery of streptomycin was announced,1 Hinshaw and Feldman had proved, both experimentally and clinically, that this antibiotic has a unique suppressive effect on tuberculous infections.2 During the last three years, the results of early investigations at the Mayo Clinic and at Mineral Springs Sanatorium have been confirmed by many other investigators.3 Thousands of persons with tuberculosis have been treated with streptomycin at many different institutions, much of the work being carried on by the American Trudeau Society, the United States Public Health Service and the Veterans Administration. As a result of this concerted attack, many of the problems connected with streptomycin therapy should be solved in the near future.
So many types of tuberculous infection have responded in some degree to treatment with streptomycin that use of the drug almost could be said to have diagnostic significance. In practice, however, it is